Grünenthal GmbH

http://www.grunenthal.com

26.09.2014 – 09:00
Improved pain relief for patients with severe chronic low back pain - results of a new study show 37%* more pain relief with Palexia® (tapentadol PR) compared to oxycodone/naloxone PR
Aachen (ots) - EMBARGO: This information is for European healthcare professionals only. Not intended for UK audience. Low back pain is one of the most common chronic pain conditions. Studies have shown that up to 85% of people worldwide will suffer from back pain during their lives.(1) A high percentage of severe ...
mehr
25.08.2014 – 09:10
New Palexia® study confirms effective pain relief in long-term use / Chronic pain patients benefit from long-term tapentadol treatment
Aachen (ots) - - EMBARGO: This information is for healthcare professionals only. Not intended for UK audience. - A recent study published in the medical journal "Current Medical Research and Opinion"* has results that are good news for chronic pain patients. This new trial was designed to meet real-life conditions ...
mehr
08.04.2014 – 10:16
Grünenthal and Pain Alliance Europe urge EU and national authorities to improve chronic pain management
Aachen/Brussels (ots) - Multi-stakeholder views on chronic pain presented in the European Parliament / Call to Action to fight chronic pain On the occasion of an exhibition and cocktail reception hosted by Petru Luhan, Member of the European Parliament and winner of the MEP award for Health 2013, a multi- ...
mehr
16.12.2013 – 14:05
Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®
Aachen, Germany / Redwood City (California), USA (ots) - Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self- administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, ...
mehr
22.05.2013 – 11:07
Grünenthal presents a new website for the topical treatment of postherpetic neuralgia (PHN)
Aachen (ots) - Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabbing, or shooting pain, and caused by a previous herpes zoster infection (commonly known as shingles). The new ...
mehr
04.12.2009 – 12:03
Supporting innovative pain research / EFIC-Grunenthal Grant 2009 awarded to five young scientists
Aachen, Germany (ots) - The European Federation of Chapters of the International Association for the Study of pain (EFIC) and the pharmaceutical company Grunenthal awarded the EFIC-Grunenthal Grant to five young European scientists. The grant will provide financial support for their future projects in ...
mehr

13.06.2008 – 11:05
Treating pain effectively - New study results confirm improved gastrointestinal tolerability of tapentadol
Paris, France / Aachen, Germany (ots) - Results from two phase III clinical studies of tapentadol immediate release tablets (IR) suggest a significantly improved gastrointestinal tolerability(1) as well as safety(2) profile compared to oxycodone HCl IR. The data were presented by the German pharmaceutical ...
mehr
11.10.2007 – 14:05
Micropill Belara® improves impure skin
Paris (ots) - At this year's 7th congress of the European Society of Gynaecology (Paris, 10-14 October 2007), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the dermatological CEFIS-Study* of the University of Hamburg shows an impressive cosmetic improvement of impured skin due to the anti-androgenic properties of ...
mehr
01.10.2007 – 14:05
Centrally acting analgesic tapentadol - latest phase II data for the treatment of acute postoperative pain presented
Aachen (ots) - At this year's 4th World Congress of the World Institute of Pain (WIP), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one molecule, μ-receptor ...
mehr

17.07.2007 – 11:45
Grunenthal signs trimegestone licensing agreement for oral contraception
Aachen (ots) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi-aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed as a new oral contraceptive component derived from natural ...
mehr
21.06.2007 – 12:14
Phase II data show efficacy and tolerability of tapentadol in chronic pain treatment
Aachen (ots) - The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, a centrally acting analgesic, ...
mehr
30.01.2007 – 10:12
Grünenthal GmbH extends licensing agreement with Ortho McNeil Pharmaceutical, Inc. for tapentadol in Japan
Aachen, Germany (ots) - Grünenthal GmbH announced that it has extended a licensing agreement with Ortho-McNeil Pharmaceutical, Inc. for tapentadol to include the Japanese market. Ortho-McNeil Pharmaceutical plans to arrange for the development of tapentadol for marketing in Japan. Ortho-McNeil"s affiliate, ...
mehr

10.01.2007 – 09:15
Versatis® lidocaine medicated plaster approved by MHRA
Aachen, Germany (ots) - In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis®, a novel 5 % lidocaine medicated plaster, for the treatment of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN), developed by the German drug company Grünenthal. Following this national approval of Versatis® and its national launch on January, ...
mehr
06.06.2006 – 09:30
Grünenthal GmbH presents tapentadol, a novel centrally acting analgesic, at the 25th Annual Scientific Meeting of The American Pain Society
Aachen (ots) - Tapentadol would be the first new molecular entity in the class of oral centrally acting analgesics to enter medical practice in over 25 years. At the American Pain Society Meeting in San Antonio, Texas, Grünenthal GmbH presented positive results on preclinical and early clinical studies of ...
mehr